Generic Program Is Biggest Extra Item In Senate User Fee Reauthorization Bill

US FDA would need additional appropriations to cover all activities contemplated in the legislation – and the bill appears to need a pay-for because it increases the deficit.

FDA entrance sign 2016

The US Congressional Budget Office (CBO) has concluded that FDA would need additional resources beyond user fees to carry out all the programs envisioned in the Senate's user fee reauthorization bill, with activities related to generic drugs accounting for much of them.

CBO's score estimates that, "assuming appropriation actions consistent with the bill," FDA would spend an additional $1.24 bil....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

More from Biosimilars & Generics